Monitor engraftment of maternal T cells in patients with severe combined immunodeficiency (SCID) prior to allogenic stem cell transplantation.
Polymerase Chain Reaction/Fragment Analysis
New York DOH Approval Status
Lavender (EDTA), Pink (K2EDTA), or Yellow (ACD Solution A).
Transport 3 mL whole blood. (Min: 2 mL) Increase the amount of blood submitted for patients with low cell counts.
Ambient. Also acceptable: refrigerated. Ship overnight. Specimens should be received within 24 hours of collection for optimal isolation of T cells.
Clotted or hemolyzed specimens.
Please provide the results and date of the patient's most recent WBC and differential counts.
Room temperature: 72 hours; Refrigerated: 72 hours; Frozen: Unacceptable
|Type Maternal||Maternal cells only.|
|Type Patient||Patient cells only.|
|Mixed||Patient and Maternalt cells present. Semi-quantitative results of percentage of patient and maternal cells will be reported.|
Background Information: for Maternal T Cell Engraftment in SCID
Indication: Severe combined immunodeficiency (SCID) patients lack T cells and cannot recognize and reject maternal T cells from maternal-fetal transfusion. Maternal T cells can proliferate in the absence of host T cells, leading to difficulty in determining the host T-cell numbers required for the diagnosis of SCID and/or can cause graft-versus-host disease (GVHD)-line presentation.
Methodology: PCR followed by capillary electrophoresis. Specimens are analyzed using 15 autosomal markers (D8S1179, D21S11, D7S820, CSF1PO, D3S1358, THO1, D13S317, D16S539, D2S1338, D19S433, vWa, TPOX, D18S51, D5S818, and FGA) and one gender marker (amelogenin).
Limit of Detection: 2 percent of minor cell population.
Limitations: Diagnostic errors can occur due to rare sequence variations.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
To complete Maternal T Cell Engraftment in SCID testing, samples should be collected to perform the following three tests: (1) A buccal swab or brush collected from the patient for Maternal T Cell Engraftment in SCID, Pre-Engraftment Specimen (ARUP test code 2014694), used as a genetic baseline for the patient. (2) A peripheral blood sample from the biological mother for Maternal T Cell Engraftment in SCID, Maternal Specimen (ARUP test code 2014704), used as a genetic baseline for the mother. (3) A peripheral blood sample collected from the patient for Maternal T Cell Engraftment in SCID (ARUP test code 2014699). T cells isolated from the blood sample will be genotyped for comparison to the patient and biological mother baseline genotypes. If T-cell sorting is not completed on the blood sample before submission of Maternal T Cell Engraftment in SCID (ARUP test code 2014699), BMT Cell Isolation (ARUP test code 2005498) will be added to each order of Maternal T Cell Engraftment in SCID (ARUP test code 20146990). Additional charges apply for cell isolation.
81268; If cell sorting is performed, add 88184
|Component Test Code*||Component Chart Name||LOINC|
|2014700||Specimen, Maternal Engraftment|
|2014701||Mat Engraftment, Informative Loci|
|2014702||Maternal Engraftment, Interpretation|
- Maternal engraftment
- SCID engraftment